A retrospective study of Yiqibushenhuoxue decoction for the treatment of chronic obstructive pulmonary disease
| Autor: | Xuehui Wang, Liqin Wang, Zhuying Li, Chun-Yan Tian |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male medicine.medical_specialty Vital capacity Vital Capacity Observational Study Walk Test chronic obstructive pulmonary disease 03 medical and health sciences FEV1/FVC ratio Pulmonary Disease Chronic Obstructive Young Adult 0302 clinical medicine Quality of life Internal medicine Forced Expiratory Volume medicine Humans 030212 general & internal medicine Exertion Adverse effect Lung Salmeterol Xinafoate Aged Retrospective Studies COPD Exercise Tolerance business.industry effect Retrospective cohort study General Medicine Middle Aged medicine.disease Yiqibushenhuoxue decoction respiratory tract diseases Bronchodilator Agents Respiratory Function Tests Dyspnea Treatment Outcome 030228 respiratory system Quality of Life Female Salmeterol business medicine.drug Research Article Drugs Chinese Herbal |
| Zdroj: | Medicine |
| ISSN: | 1536-5964 0025-7974 |
| Popis: | This retrospective study aimed to investigate the effect and safety of Yiqibushenhuoxue decoction (YQBSHXD) for the treatment of chronic obstructive pulmonary disease (COPD). This study involved 120 cases of patients with COPD. These cases were assigned to an intervention group and a control group equally, 60 subjects each group. Patients in both groups underwent Salmeterol. In addition, the cases in the intervention group also received YQBSHXD. All cases received a total of 12 weeks treatment. The primary outcome of lung function was measured by forced expiratory volume in 1 second (FEV1), and FEV1/forced vital capacity (FVC). The secondary outcomes included severity of dyspnea on exertion, evaluated by 6-minute walk test (6MWT) with measurement of 6-minute walk distance (6MWD); and quality of life, assessed by the St. George's Respiratory Questionnaire (SGRQ). In addition, adverse events (AEs) were also recorded in this study. All outcome measurements were assessed before and after 12-week treatment. After 12-week treatment, cases in the intervention group underwent YQBSHXD did not show better outcome in lung function improvement, measured by the FEV1 (P = .11), and FEV1/FVC (P = .15), compared with those in the control group. However, YQBSHXD may help to alleviate the severity of dyspnea on exertion, as measured by 6MWD (P = .03), and to improve the quality of life, as assessed by the SGRQ (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|